| Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. | |
| | |
MedLine Citation:
|
PMID: 16330566 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Few data exist on the medicoeconomic usefulness of PET in the management of metachronous liver metastases from colorectal cancer. This study was designed to assess the cost-effectiveness of PET in the diagnosis and staging of patients with metachronous liver metastases of colorectal cancer using a decision analysis model. METHODS: Two alternatives were compared: CT and CT associated with PET (CT+PET). Transition probabilities were estimated from published data and consultations with experts. Survival data were provided by the Burgundy Digestive Cancer Registry (France). Costs of imaging techniques and treatments were assessed using reimbursements from the French health care insurance for the year 2004. Evaluation criteria included incremental cost-effectiveness ratios and the proportion of unnecessary operations avoided in patients without metachronous liver metastases. RESULTS: CT+PET was the most cost-effective strategy, presenting an expected incremental cost saving of 2,671 (approximately $3,213) per patient, for the same level of expected effectiveness as CT alone (1.88-y life expectancy per patient). Sensitivity analyses performed on epidemiologic and economic parameters showed that this model was robust. The model also suggested that CT+PET could avoid exploratory surgery for 6.1% of patients-that is, 88.4% risk reduction compared with CT alone. CONCLUSION: PET for diagnosis and staging does not generate additional survival effectiveness compared with CT alone. However cost savings associated with its use and the improvement of therapeutic management therefore justify its generalization in clinical practice. |
| | |
Authors:
|
Catherine Lejeune; Marie J Bismuth; Thierry Conroy; Catherine Zanni; Pierre Bey; Laurent Bedenne; Jean Faivre; Patrick Arveux; Francis Guillemin |
Related Documents
:
|
17318606 - Staging of renal cell carcinoma. 19434386 - Magnetic resonance imaging of pelvic organ prolapse: comparing pubococcygeal and midpub... 18197136 - Identification of distant metastases with positron-emission tomography-computed tomogra... 15827416 - Pet/ct imaging of metastatic deposit in vertebral paget's disease. 18421106 - Geometry-based image retrieval in binary image databases. 2154286 - Magnetic resonance imaging (mri) effects on rat pineal neuroendocrine function. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 46 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-12-06 Completed Date: 2006-02-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 2020-8 Citation Subset: IM |
Affiliation:
|
INSERM EMI (Equipe Mixte INSERM) 0106, Dijon, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Colorectal Neoplasms
/
pathology,
radionuclide imaging* Cost-Benefit Analysis / methods* Decision Support Techniques* Fluorodeoxyglucose F18 / diagnostic use* Humans Liver Neoplasms / pathology, radionuclide imaging* Neoplasm Metastasis Neoplasm Staging / methods* Neoplasms / epidemiology Positron-Emission Tomography / economics*, methods* Sensitivity and Specificity Time Factors Tomography, X-Ray Computed Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 18F-FDG PET in detecting metastatic infectious disease.
Next Document: Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcino...